Novo Nordisk to build North Carolina plant to add 1,000 jobs
CLAYTON, N.C. (AP) — Novo Nordisk, the maker of Ozempic and Wegovy, announced on Monday that it plans to add 1,000 jobs when another company manufacturing plant is built in …
CLAYTON, N.C. (AP) — Novo Nordisk, the maker of Ozempic and Wegovy, announced on Monday that it plans to add 1,000 jobs when another company manufacturing plant is built in …
Novo Nordisk on Tuesday said its hugely popular weight-loss drug Wegovy has been approved in China, the world’s second-largest economy and the country estimated to hold the highest number of …
(NewsNation) — The World Health Organization (WHO) has issued a warning about fake weight loss medication claiming to contain the active ingredients in the diabetes drug Ozempic and weight loss …
Falsified weight loss and diabetes medicines have been detected in some countries, the World Health Organisation (WHO) warned in a statement on Thursday. The falsified medicine is semaglutide, a type …
The World Health Organization and drug maker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines. The WHO said Thursday …
Ozempic users are consuming fewer calories, and as a result are buying smaller sizes to fit their newly svelte bodies or, in some cases, are choosing more revealing fashion styles. …
(NewsNation) — As weight loss drugs like Ozempic and Wegozy are soaring in popularity, some insurers are looking to drop the medications, possibly costing patients thousands in out-of-pocket expenses. Blue …
Chamundi Selvaraj takes a weekly dose of Ozempic because she’s afraid of dying from diabetes-related kidney failure like her mother and four aunts, who all passed away in their 60s. …
The popular weight-loss drug Wegovy has been available in Canada since early May, but anybody hoping to use it will have to shell out about $400 a month. One advocate says …
Going down to South Park… The latest “South Park” special, called “The End of Obesity,” now streaming on Paramount+, takes aim at the Ozempic craze – and brutally targets the …